This activity is supported by an unrestricted educational grant from Oyster Point Pharma.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, complete the evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers: Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements: 4GB+ RAM
Recommended internet speed 5Mbps+
Vance Thompson, MD, FACS (Moderator)
Founder, Vance Thompson Vision
Professor of Ophthalmology
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD
Preeya K. Gupta, MD
Founder and Director of Triangle Eye Consultants
Wake Forest and Cary, North Carolina
Edward J. Holland, MD
Professor of Ophthalmology
University of Cincinnati
Director of the Cornea Service
Cincinnati Eye institute
Cincinnati, Ohio
John D. Sheppard, MD, MMSc
President, Virginia Eye Consultants
Professor of Ophthalmology, Microbiology, Molecular Biology
Eastern Virginia Medical School
Partner & Board of Directors, CVT Vision Partners
Norfolk, VA
David L. Wirta, MD
Principal Investigator/Medical Director
Eye Research Foundation
Newport Beach, CA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Vance Thompson, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Acufocus, Alcon Vision, Allergan, Allotex, Avellino, Avisi Technologies, Bausch + Lomb, BRIM Biotechology, Carl Zeiss Meditec, Centricity, Conjtac, CSO, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, Glaukos, Imprimis, iVeena, Johnson & Johnson Vision, Leica, Melt Pharmaceuticals, Ocular Innovations, OneFocus, ORA, Oyster Point Pharma, Percept, ReFocus, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, Visus, and Vivior. Grant/Research Support: Acufocus, Alcon Vision, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Centricity, Equinox, EyeGate Pharma, Glaukos, Johnson & Johnson Vision, Sight Sciences. Speakers Bureau: Acufocus, Alcon Vision, Glaukos, Johnson & Johnson Vision. Shareholder: Acufocus, Al Optics, Allotex, Avellino, Avisi Technologies, Centricity, Conjtac, D&D Biopharmaceuticals, Equinox, Euclid Systems, Expert Opinion, eyeBrain Medical, Eyedetec, EyeGate Pharma, Eyesafe, FemtoVision, Foresight Robotics, iVeena, Melt Pharmaceuticals, Ocular Innovations, OneFocus, Oyster Point Pharma, Percept, RxSight, Sight Sciences, Stuart Therapeutics, Tarsus Rx, TearClear, TearOptix, TherOptix, Treehouse Health, Veracity, Visant, and Vivior
Preeya K. Gupta, MD, has no financial agreements with commercial interests.
Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Alcon Vision, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, BRIM biotech, Carl Zeiss Meditec, Claris Bio, Corneat, CorneaGen, Dompé, Expert Opinion, Eye Point Pharmaceuticals, Glaukos, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck, Novartis NIBR, Novartis, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point Pharma, Precise Bio, Prometic Biotherapeutics, ReGentree, Retear, Senju, Shire, Sight Sciences, Slack, Tarsus, TearLab Research, Vomaris, and W.L. Gore and Associates. Grant/Research Support: Alcon Vision, Mati Therapeutics, Novartis, Omeros, Senju, and Shire. Speaker’s Bureau: Alcon Vision, Novartis, Omeros, Senju, and Shire.
John D. Sheppard, MD, MMSc, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Aldeyra Therapeutics, Allergan, Allysta Pharmaceuticals, Avedro, Bausch + Lomb, Bio-Tissue, Bruder Healthcare, Clementia Pharmaceuticals, Dompé, EyeGate, EyePoint Pharmaceuticals, Glaukos, Hovione, Johnson & Johnson Vision, Kala Pharmaceuticals, Lacri Sciences, LayerBio, Mallinckrodt, Novaliq, Novartis, Noveome Biotherapeutics, Ocular Therapeutix, Omeros, Oyster Point Pharma, Quidel, Science Based Health, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceuticals USA, TearLab, Tear Solutions, and TopiVert. Grant/Research Support: Alcon Vision, Bausch + Lomb, Chengdu Kanghong Pharmaceutical Group, Clearside Biomedical, EyeGate, Hovione, Kala Pharmaceuticals, Mallinckrodt, and Visus Pharmaceuticals. Speaker’s Bureau: Alcon Vision, Bausch + Lomb, Bio-Tissue, Dompé, and Mallinckrodt. Stock/Shareholder: Claris Bio, Doctors Optimal Formula, Eyedetec Medical, EyeRxResearch, Eyevance, Lacrisciences, LayerBio, Noveome Biotherapeutics, Oyster Point Pharma, ProVision Network, Rapid Pathogen Screening, Scientifically Developed Solutions, Strathspey Crowne, and TearLab.
David L. Wirta, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AbbVIe, Eyenovia, and Novartis. Grant/Research Support: Allergan, Novartis, Ora, and Oyster Point Pharma.
The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Cataract & Refractive Surgery Today, MillennialEYE, or Oyster Point Pharma.
